Neurotrope, Inc. announced that on July 16, 2014, its Board of Directors appointed Co-Chairmen Charles S. Ramat and Paul Freiman as Co-Chief Executive Officers on an interim basis, effective immediately. Messrs. Ramat and Freiman replace Dr. James New, who is no longer Chief Executive Officer of Neurotrope Bioscience, Inc., or the company and whose employment agreement with Neurotrope Bioscience Inc. terminated as of July 16, 2014.

Dr. New remains a member of the company's Board of Directors. Mr. Ramat is currently a private investor and has extensive operational and general business experience in several industries including: biotechnology, medical devices, commercial finance, real estate and mobile communications. From December 2009 until December 2013, Mr. Ramat was a principal investor and consultant to Continental Home Loans.

Mr. Freiman is currently an independent pharmaceutical and biotechnology industry consultant. He serves as Chairman of Chronix BioMedical and is a member of the NovaBay Pharmaceutical Board of Directors.